XingImaging is appointed as the Imaging Core Lab for the ambitious Phase II Alzheimer's Tau Platform trial, a critical study in Alzheimer's disease research.

A strategic partnership among SynuSight Biotech, ABLi Therapeutics, and XingImaging aims to enhance clinical trials of risvodetinib through advanced imaging techniques for Parkinson's disease.

XingImaging has partnered with SynuSight to develop a PET tracer for Parkinson’s disease, supported by a $3.84M grant from The Michael J. Fox Foundation.

XingImaging's NX PET Camera promises to redefine Parkinson's disease research with high-resolution imaging and advanced analytics, essential for early biomarker detection.

XingImaging has unveiled the NX PET Camera, a state-of-the-art imaging system designed to improve Parkinson's disease research and treatment.

XingImaging has unveiled a state-of-the-art research facility in New Haven, enhancing clinical studies with advanced imaging technologies. This hub will support life-saving treatment development.

Developing disease-modifying therapies for Parkinson's and related neurodegenerative diseases through targeting Abelson Tyrosine Kinases.

SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment SHANGHAI, ATLANTA and NEW HAVEN, Conn. , Jan. 5, 2026 /PRNewswire/ -- SynuSight Biotech ("SynuSight"), a biotechnology...

NEW HAVEN, Conn., April 30, 2025 /PRNewswire/ -- XingImaging, a MITRO company, a pioneer in advanced research imaging, radiopharmaceutical services, and medical imaging technology, proudly announces the launch of the **NX PET Camera**, a breakthrough in positron emission tomography (PET)...

NEW HAVEN, Conn., Jan. 13, 2025 /PRNewswire/ -- XingImaging, a MITRO company, a leader in advanced research imaging and radiopharmaceutical services, is excited to announce the opening of its new state-of-the art research facility in New Haven,…